Kura Oncology, Inc. announced the appointment of Helen Collins, M.D., to its board of directors as Class II director of the company. Dr. Collins served as Chief Medical Officer at Five Prime Therapeutics. Dr. Collins joins the Kura board of directors with more than 25 years of medical experience. Most recently, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics.